Concerns about the potential side effects of Biogen Idec Inc. (NASDAQ:BIIB)’s key multiple-sclerosis pill Tecfidera overshadowed the strong third-quarter results the biotech company Tecfidera is an essential part of Biogen’s goal to become the dominant maker of multiple-sclerosis treatments, a group of drugs that command high prices and that patients typically take for years. Tecfidera’s sales in the third quarter more than doubled to $787.1 … Continue reading Momentum Stocks : Biogen Idec Inc. (NASDAQ:BIIB), Texas Instruments Inc. (NASDAQ:TXN), Brookfield Property Partners L.P. (NYSE:BPY), Virtus Investment Partners, Inc. (NASDAQ:VRTS), STZ